Preservation of slow wave sleep as a neuroprotective strategy in aging

Abstract:Preservation of normal sleep, proper nutrition and physical exercise are key elements in maintaining healthy aging. Their deficiency predisposes to fragility, a pathophysiological condition that leads to greater vulnerability to diseases and adverse effects, resulting from the loss of h...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Sociedad Española de Medicina Antienvejecimiento y Longevidad 2019
Materias:
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/8825
Aporte de:
id I33-R139123456789-8825
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic MELATONINA
PREVENCIÓN
ENVEJECIMIENTO
BENZODIAZEPINAS
HOMEOSTASIS
TRASTORNOS DEL SUEÑO
spellingShingle MELATONINA
PREVENCIÓN
ENVEJECIMIENTO
BENZODIAZEPINAS
HOMEOSTASIS
TRASTORNOS DEL SUEÑO
Cardinali, Daniel Pedro
Preservation of slow wave sleep as a neuroprotective strategy in aging
topic_facet MELATONINA
PREVENCIÓN
ENVEJECIMIENTO
BENZODIAZEPINAS
HOMEOSTASIS
TRASTORNOS DEL SUEÑO
description Abstract:Preservation of normal sleep, proper nutrition and physical exercise are key elements in maintaining healthy aging. Their deficiency predisposes to fragility, a pathophysiological condition that leads to greater vulnerability to diseases and adverse effects, resulting from the loss of homeostasis and a decreased functional reserve. Melatonin, a molecule of extraordinary phylogenetic conservation present in all known aerobic organisms, is effective both as a chronobiotic and a cytoprotective agent in aging. The late afternoon increase of melatonin “opens the sleep doors” every night and its therapeutic use as a guardian of slow wave sleep has been demonstrated. There is a growing use of hypnotics such as benzodiazepines (BZP) and Z drugs, which have shown a deleterious effect on slow wave sleep and, due to their tolerance and dependence, are a serious problem of public health. Thirty years ago, we demonstrated the interaction of melatonin with central BZP receptors and in 1997 we published the first demonstration of the reduction of BZP consumption in melatonin-treated elderly subjects. The approval by the EMA of melatonin as a drug in 2007 has allowed obtaining pharmacoepidemiologic information on this topic. Several studies have found that more than half of patients treated with BZP and who had started treatment with melatonin abandoned BZP consumption. In another study in 9 European countries it was concluded that campaigns to reduce BZP consumption fail if there is no availability and reimbursement of the melatonin received in replacement. The data support the use of melatonin in patients who chronically use BZP or Z-drugs. Melatonin has no addictive and tolerant effects and thus becomes the treatment of choice for the preservation of slow wave sleep in the elderly.
format Artículo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
author_sort Cardinali, Daniel Pedro
title Preservation of slow wave sleep as a neuroprotective strategy in aging
title_short Preservation of slow wave sleep as a neuroprotective strategy in aging
title_full Preservation of slow wave sleep as a neuroprotective strategy in aging
title_fullStr Preservation of slow wave sleep as a neuroprotective strategy in aging
title_full_unstemmed Preservation of slow wave sleep as a neuroprotective strategy in aging
title_sort preservation of slow wave sleep as a neuroprotective strategy in aging
publisher Sociedad Española de Medicina Antienvejecimiento y Longevidad
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/8825
work_keys_str_mv AT cardinalidanielpedro preservationofslowwavesleepasaneuroprotectivestrategyinaging
bdutipo_str Repositorios
_version_ 1764820528574496770